

Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

<https://marketpublishers.com/r/MA55646E68AEN.html>

Date: June 2018

Pages: 197

Price: US\$ 700.00 (Single User License)

ID: MA55646E68AEN

Abstracts

Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer disease clinical trials. The research work analyzes the ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials.

Scope of the Report-

Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials across regions

Trial information by Phase and Subjects recruited

Trial information by status, type, sponsor type

Drugs used for treatment of Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer

Both observational and interventional trials analyzed

Leading companies and universities participating in Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials

Reasons to Buy

Track competition and design competitive advantages

Identify right partners to associate with for further research

Evaluate potential opportunities available in further clinical trials of the disease

Formulate business development strategies through success rates of clinical trials

Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

- 1.1 List of Figures
- 1.2 List of Tables

2 KEY FINDINGS, 2018

- 2.1 Snapshot
- 2.2 Overview of Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials

3 CLINICAL TRIALS TRENDS TO 2022

- 3.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase
- 3.2 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Type
- 3.3 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

- 4.1 Region wise Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
- 4.2 Top 10 Countries conducting Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
- 4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

- 5.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Sponsor Type
- 5.2 Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Subjects by Sponsor Type
- 5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by year

6.2 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase

6.3 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Trial Type

6.4 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

7.2 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

7.3 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

7.4 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions

8.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Country

Figure 2: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Phase of Development, 2018

Figure 3: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Status, 2018

Figure 4: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type, 2018

Figure 5: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials Split by Region, 2000-2018

Figure 6: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type of Economy, 2018

Figure 7: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Phase, 2018

Figure 8: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Trial Type, 2018

Figure 9: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Recruitment Status, 2018

Figure 10: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018

Figure 11: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Type of Sponsors

Figure 12: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Leading Sponsors

List Of Tables

LIST OF TABLES

Table 1: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018

Table 2: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Economy Type, 2018

Table 3: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Region, 2018

Table 4: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trial Participations of Top 10 Countries, 2018

Table 5: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials in Emerging and Developing Economies, 2018

Table 6: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

Table 7: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

Table 8: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

Table 9: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company

I would like to order

Product name: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

Product link: <https://marketpublishers.com/r/MA55646E68AEN.html>

Price: US\$ 700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA55646E68AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

